Paper Details

  1. Home
  2. Paper Details

A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD.

Author: GentryE, GreenbergD, KarpelJ P, PesinJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Both ipratropium bromide and metaproterenol sulfate are effective medications for acute exacerbations of chronic obstructive pulmonary disease when administered via a metered dose inhaler. However, ipratropium may be safer as it did not cause a decline in blood oxygenation.
Paper Details　
Original Abstract of the Article :
Thirty-two patients presenting with acute exacerbations of chronic obstructive pulmonary disease were entered into the following double-blind, crossover study. First (time 0), patients inhaled either ipratropium bromide (54 micrograms) or metaproterenol sulfate (1.95 mg) via a metered dose inhaler (...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1378/chest.98.4.835

データ提供：米国国立医学図書館（NLM）

Ipratropium Bromide vs. Metaproterenol Sulfate: Navigating the Desert of COPD Exacerbations

This research compares the effectiveness and safety of ipratropium bromide and metaproterenol sulfate in treating acute exacerbations of chronic obstructive pulmonary disease (COPD). Imagine a camel caravan facing a sudden sandstorm, needing immediate relief and protection. Similarly, individuals experiencing acute COPD exacerbations require prompt and effective treatment to manage their symptoms. This study evaluates the effectiveness of two commonly used medications, ipratropium bromide and metaproterenol sulfate, in alleviating COPD symptoms.

Finding the Right Oasis: Effective Treatment for COPD Exacerbations

The study found that both ipratropium bromide and metaproterenol sulfate were effective in improving pulmonary function in patients with acute COPD exacerbations. However, ipratropium bromide was associated with a smaller decline in blood oxygenation, suggesting that it may be a safer option for some patients. It's like finding two oases in a desert, each offering relief but with slightly different characteristics.

Navigating the Desert of COPD: Choosing the Right Medication

This research highlights the importance of considering individual patient factors when choosing a medication for acute COPD exacerbations. It emphasizes the need to carefully weigh the potential benefits and risks of different treatment options, taking into account factors such as blood oxygenation and overall safety. It's like navigating a desert with multiple paths, where the best choice depends on the specific needs and circumstances of the traveler.

Dr. Camel's Conclusion

This study underscores the importance of personalized medicine in treating COPD, recognizing that the most effective approach can vary from patient to patient. It reminds us that finding the right medication for managing COPD exacerbations requires careful consideration and a deep understanding of the nuances of the disease.

Date :
  1. Date Completed 1990-11-15
  2. Date Revised 2019-05-14
Further Info :

Pubmed ID

2145136

DOI: Digital Object Identifier

10.1378/chest.98.4.835

Related Literature

Article Analysis
・Effects of metaproterenol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.